The Plaque Psoriasis (Psoriasis Vulgaris) drugs in development market research report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Plaque Psoriasis (Psoriasis Vulgaris). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued products.

GlobalData tracks 161 drugs in development for Plaque Psoriasis (Psoriasis Vulgaris) by 133 companies/universities/institutes. The top development phase for Plaque Psoriasis (Psoriasis Vulgaris) is phase i with 55 drugs in that stage. The Plaque Psoriasis (Psoriasis Vulgaris) pipeline has 161 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Plaque Psoriasis (Psoriasis Vulgaris) pipeline products market are: Biocon, Boehringer Ingelheim International and CSPC Pharmaceutical Group.

The key targets in the Plaque Psoriasis (Psoriasis Vulgaris) pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A), and Interleukin 23 Subunit Alpha (Interleukin 23 Subunit p19 or IL23A).

The key mechanisms of action in the Plaque Psoriasis (Psoriasis Vulgaris) pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with 25 drugs in Pre-Registration. The Plaque Psoriasis (Psoriasis Vulgaris) pipeline products include 12 routes of administration with the top ROA being Subcutaneous and nine key molecule types in the Plaque Psoriasis (Psoriasis Vulgaris) pipeline products market including Monoclonal Antibody, and Small Molecule.

Plaque Psoriasis (Psoriasis Vulgaris) overview

Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a silvery-white scale. Plaque psoriasis commonly affects areas like the elbows, knees, scalp, and lower back, but it can occur anywhere on the body. The condition is not contagious, and its severity can vary from mild to severe. Treatment options include topical creams, phototherapy, systemic medications, and biologics, aimed at managing symptoms and controlling inflammation.

For a complete picture of Plaque Psoriasis (Psoriasis Vulgaris)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.